Regentis Biomaterials Prices $6.5M Private Placement

Key Highlights

• Regentis Biomaterials Ltd. priced a private placement of ordinary shares and warrants.
• The offering is expected to raise approximately $6.5 million in gross proceeds.
• The company will issue 1,844,543 ordinary shares and pre-funded warrants to purchase up to 12,600 ordinary shares.
• Accompanying the shares and pre-funded warrants are ordinary warrants to purchase up to 1,857,143 ordinary shares.
• The purchase price is $3.50 per ordinary share and accompanying ordinary warrant, and $3.4999 per pre-funded warrant and accompanying ordinary warrant.
• Proceeds will fund pivotal clinical trial for GelrinC, FDA submission preparation, technology platform advancement, and European market entry.
• ThinkEquity LLC acted as the exclusive placement agent for the offering.